121221-08-7

Basic information

• Product Name: 2-CHLORO-N-QUINOLIN-5-YLACETAMIDE
• Synonyms: 2-chloro-N-5-quinolinylacetamide(SALTDATA: FREE);2-chloro-N-5-quinolinylacetamide
• CAS NO: 121221-08-7
• Molecular Formula: C₁₁H₉ClN₂O
• Molecular Weight: 220.65
• Mol File: 121221-08-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 157 °C
• Boiling Point: 460.4°Cat760mmHg
• Flash Point: 232.3°C
• Appearance: /
• Density: 1.368g/cm³
• Vapor Pressure: 1.16E-08mmHg at 25°C
• Refractive Index: 1.685
• Storage Temp.: -20°C, Inert atmosphere
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Very Slightly)
• PKA: 11.58±0.43(Predicted)
• CAS DataBase Reference: 2-CHLORO-N-QUINOLIN-5-YLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-QUINOLIN-5-YLACETAMIDE(121221-08-7)
• EPA Substance Registry System: 2-CHLORO-N-QUINOLIN-5-YLACETAMIDE(121221-08-7)

Safety Data

• Hazardous Substances Data: 121221-08-7(Hazardous Substances Data)

Usage

Description

2-Chloro-N-quinolin-5-ylacetamide is a chemical compound that serves as a key reagent in the synthesis of pharmaceuticals. It is characterized by its chloro and quinolinyl groups, which contribute to its unique chemical properties and potential applications in the medical field.

Uses

Used in Pharmaceutical Industry:
2-Chloro-N-quinolin-5-ylacetamide is used as a reagent for the preparation of butyrylcholinesterase selective inhibitors. These inhibitors are crucial for the development of treatments targeting Alzheimer's disease, a progressive neurodegenerative disorder affecting memory and cognitive function.
In the context of Alzheimer's disease treatment, butyrylcholinesterase selective inhibitors play a significant role in managing the symptoms and potentially slowing the progression of the disease. By inhibiting the enzyme butyrylcholinesterase, these inhibitors can help maintain the balance of neurotransmitters in the brain, thereby improving cognitive function and overall quality of life for patients.

InChI:InChI=1/C11H9ClN2O/c12-7-11(15)14-10-5-1-4-9-8(10)3-2-6-13-9/h1-6H,7H2,(H,14,15)

Upstream product

• 611-34-7 5-Aminoquinoline 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 347196-40-1 (R)-2-(3-Methylpiperazin-1-yl)-N-(quinolin-5-yl)acetamide 
• 1242606-91-2 C₃₀H₂₈N₆O 

Relevant articles and documents

AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS

Disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response. Also disclosed herein are methods, pharmaceutical compositions, and vaccines for inducing an immune response.

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Four series of hypoxia-inducible factor-1 alpha (HIF-1α) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated. To address the structure and activity relationship of each derivative, extensive structural changes were made. HRE luciferase reporter assay demonstrated that 12 modified compounds showed superior HIF-1α inhibitory activity. Among them, compound C6 exhibited the best features: firstly, the strongest HIF-1α inhibitory activity (IC50 = 0.05 μM, 5-fold higher than that of celastrol); secondly, lower cytotoxicity (22-fold lower, C6-16.85 μM vs celastrol-0.76 μM). Thus, the safety factor of C6 was about 112 times higher than that of celastrol. Western blot assay indicated that C6 may inhibit the expression of HIF-1α protein in cells. Additionally, C6 hindered tumor cell cloning, migration and induced cell apoptosis. It is worth mentioning that in the mouse tumor xenograft model, C6 (10 mg/kg) displayed good antitumor activity in vivo, showing a better inhibition rate (74.03%) than the reference compound 5-fluorouracil (inhibition rate, 59.58%). However, the celastrol treatment group experienced collective death after four doses of the drug. Moreover, C6 minimally affected the mouse weight, indicating that its application in vivo has little toxic effect. H&E staining experiments show that it could also exacerbate the degree of tumor cell damage. The results of water solubility experiment show that the solubility of C6 is increased by 1.36 times than that of celastrol. In conclusion, C6 is a promising antitumor agent through HIF-1α pathway.

COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE

Disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response. Also disclosed, herein are methods, pharmaceutical compositions, and vaccines for inducing an immune response.